Analyst consensus rating
Hemab Therapeutics Analyst Rating: none
COAG is rated none by 5 analysts with a $61.20 target. As of 2026-09-02.
Direct answer
Hemab Therapeutics's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $61.20.
Forecast evidence checked September 2, 2026.
Get free Hemab Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $45.01
- Average price target
- $61.20
- High price target
- $65.00
- Low price target
- $58.00
- Low target gap
- +28.9%
- Target upside
- +36%
- High target gap
- +44.4%
- Target range width
- 15.6%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Hemab Therapeutics?
Hemab Therapeutics has a verified none consensus. The same dataset has an average price target of $61.20.
How far are Hemab Therapeutics's low and high targets from the recorded price?
The low target implies +28.9%, while the high target implies +44.4%.
How many analysts are included in Hemab Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Hemab Therapeutics's target upside or downside calculated?
The average target of $61.20 is divided by the recorded price of $45.01, then one is subtracted to produce +36%. This does not guarantee a future return.
When was Hemab Therapeutics's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.